Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Yoshiko Urata"'
Autor:
Yoshihiro Hattori, Yuko Kono, Shoichi Itoh, Takako Inoue, Yoshiko Urata, Yoshitaka Kawa, Rie Tohnai, Toru Kumagai, Kazumi Nishino, Ryuji Uozumi, Satoshi Morita, Shunichi Negoro, Fumio Imamura, Miyako Satouchi
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The aim of this study was to evaluate the efficacy and safety of nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). Methods Chemotherapy-naïve patients with advanced NS
Externí odkaz:
https://doaj.org/article/888a7fee177744729ec42d5d2ad1be86
Autor:
Motoko Tachihara, Shunichi Negoro, Takako Inoue, Motohiro Tamiya, Yuki Akazawa, Takeshi Uenami, Yoshiko Urata, Yoshihiro Hattori, Akito Hata, Nobuyuki Katakami, Soichiro Yokota
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-6 (2018)
Abstract Background Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. Methods We examined the e
Externí odkaz:
https://doaj.org/article/f683f5a2b3534e7dbdafdcac607cfe42
Autor:
Nobuyuki Katakami, Toshihide Yokoyama, Satoshi Morita, Tatsuro Okamoto, Yoshiko Urata, Yoshihiro Hattori, Yasuo Iwamoto, Yuki Sato, Norihiko Ikeda, Toshiaki Takahashi, Haruko Daga, Tetsuya Oguri, Yasuhito Fujisaka, Kazumi Nishino, Shunichi Sugawara, Toshiyuki Kozuki, Masahide Oki, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
International Journal of Clinical Oncology. 28:79-88
Since the overall survival (OS) of patients enrolled in the first clinical phase III trial (WJOG5108L) was not recorded owing to time constraints, the present study (WJOG5108LFS) with a longer follow-up (66.6 months) aimed to compare OS of those trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19133fbefaa83e8a534a792d5ccb0f6
https://doi.org/10.1007/s10147-022-02266-x
https://doi.org/10.1007/s10147-022-02266-x
Autor:
Satoshi Oizumi, Shigeki Umemura, Yuichiro Ohe, Akinobu Hamada, Takamasa Hotta, Hidenori Mizugaki, Yukiko Nakamura, Yoshihito Kogure, Atsushi Horiike, Yutaka Fujiwara, Takehito Shukuya, Tatsuhiro Shibata, Yusuke Okuma, Yasuhiro Fujiwara, Mitsuo Sato, Tatsuya Yoshida, Yasuhito Fujisaka, Haruko Daga, Kazuhiko Yamada, Fumie Hosoda, Sho Saeki, Yoshiko Urata, Hiromi Nakamura, Tomoya Fukui
Publikováno v:
Lung Cancer. 128:20-25
Objectives Crizotinib is a standard treatment for advanced anaplastic lymphoma kinase (ALK)- or ROS1-fusion-gene-positive non-small cell lung cancer; however, serious adverse events (AEs), including elevated alanine aminotransferase (ALT)/aspartate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aab345c022b0e97963ce32fa71063ccc
https://doi.org/10.1016/j.lungcan.2018.12.002
https://doi.org/10.1016/j.lungcan.2018.12.002
Autor:
Miyako Satouchi, Yoshihiro Hattori, Yoshitaka Kawa, Shunichi Negoro, Yoshiko Urata, Toru Kumagai, Takako Inoue, Kazumi Nishino, Fumio Imamura, Satoshi Morita, Ryuji Uozumi, Yuko Kono, Shoichi Itoh, Rie Tohnai
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Background The aim of this study was to evaluate the efficacy and safety of nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). Methods Chemotherapy-naïve patients with advanced NSCLC were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7b69bb463a462420f656922df960846
http://europepmc.org/articles/PMC7014598
http://europepmc.org/articles/PMC7014598
Autor:
Yuki Akazawa, Soichiro Yokota, Takeshi Uenami, Shunichi Negoro, Yoshiko Urata, Nobuyuki Katakami, Akito Hata, Motoko Tachihara, Yoshihiro Hattori, Takako Inoue, Motohiro Tamiya
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-6 (2018)
BMC Cancer
BMC Cancer
Background Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. Methods We examined the efficacy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da33881f81144ebcd57fe296f24cd7b2
http://link.springer.com/article/10.1186/s12885-018-4819-2
http://link.springer.com/article/10.1186/s12885-018-4819-2
Autor:
Miyako Satouchi, Ken Uchibori, Motoko Tachihara, Chiyuki Kokan, Yoshiko Urata, Keisuke Aoe, Kazuyuki Kobayashi, Kentaro Iwanaga, Akemi Sato, Naoko Sueoka-Aragane, Satoshi Morita, Tomonori Hirashima, Nobuyuki Katakami, Shunichi Negoro, Takako Inoue, Fumio Imamura, Masahide Mori
Publikováno v:
Lung Cancer. 124:65-70
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression caused by acquir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4104cdcde8f376c37e0e4f1a5a4da861
https://doi.org/10.1016/j.lungcan.2018.07.031
https://doi.org/10.1016/j.lungcan.2018.07.031
Autor:
Yoshitaka Kawa, Shunichi Negoro, Yoshiko Urata, Miyako Satouchi, Masahiro Tsuda, Rie Tohnai, Yoshihiro Hattori, Shoichi Ito, Yuichiro Yasuda, Yuko Kono, Toshiko Sakuma
Publikováno v:
Internal Medicine
We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3249e3710c508ca7465eac3f9be304b
https://doi.org/10.2169/internalmedicine.9230-17
https://doi.org/10.2169/internalmedicine.9230-17
Autor:
Yoshiko Urata, Miho Tanaka, Rie Tohnai, Shoichi Itoh, Tatsuya Ishii, Miyako Satouchi, Yoshihiro Hattori, Yuko Kono, Yoshitaka Kawa
Publikováno v:
Respiratory investigation. 58(4)
Background Carboplatin plus nanoparticle albumin-bound paclitaxel (nab-PTX) is one of the available first-line treatments for non-small cell lung cancer (NSCLC) patients. However, the efficacy of carboplatin plus nab-PTX as second-line, remains unkno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dfb2bdf1e9cd08f6d7fd57349647bee
https://pubmed.ncbi.nlm.nih.gov/32111518
https://pubmed.ncbi.nlm.nih.gov/32111518
Autor:
Isao Goto, Satoshi Morita, Yoichi Nakanishi, Haruko Daga, Haruyasu Murakami, Takashi Seto, Nobuyuki Katakami, Masashi Kanehara, Kazuhiko Nakagawa, Norihiko Ikeda, Tetsuya Oguri, Daichi Fujimoto, Shunichi Sugawara, Fumio Imamura, Miyako Satouchi, Hideo Saka, Reiko Kaji, Naoyuki Nogami, Yasuo Iwamoto, Yoshiko Urata, Shunichi Negoro, Hiroshige Yoshioka
Publikováno v:
Journal of Clinical Oncology. 34:3248-3257
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors (TKIs) are currently approved, and both gefitinib and erlotinib are the most we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c664e1fc660d0de48274c2a5d46fa2
https://doi.org/10.1200/jco.2015.63.4154
https://doi.org/10.1200/jco.2015.63.4154